1. Home
  2. PEBK vs SPRO Comparison

PEBK vs SPRO Comparison

Compare PEBK & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peoples Bancorp of North Carolina Inc.

PEBK

Peoples Bancorp of North Carolina Inc.

HOLD

Current Price

$36.10

Market Cap

157.0M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.33

Market Cap

136.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEBK
SPRO
Founded
1912
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.0M
136.7M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
PEBK
SPRO
Price
$36.10
$2.33
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
11.2K
258.7K
Earning Date
02-11-2026
11-13-2025
Dividend Yield
2.65%
N/A
EPS Growth
3.81
N/A
EPS
3.06
N/A
Revenue
$85,500,000.00
$40,549,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.83
N/A
Revenue Growth
6.88
N/A
52 Week Low
$23.74
$0.51
52 Week High
$38.46
$3.22

Technical Indicators

Market Signals
Indicator
PEBK
SPRO
Relative Strength Index (RSI) 57.46 50.86
Support Level $36.15 $2.26
Resistance Level $38.40 $2.37
Average True Range (ATR) 0.79 0.07
MACD -0.32 0.00
Stochastic Oscillator 10.61 45.45

Price Performance

Historical Comparison
PEBK
SPRO

About PEBK Peoples Bancorp of North Carolina Inc.

Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: